Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
66 hedge funds and large institutions have $146M invested in Novelion Therapeutics Inc. Common Shares in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 10 closing their positions.
33% more capital invested
Capital invested by funds: $110M → $146M (+$36.1M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
17% more call options, than puts
Call options by funds: $252K | Put options by funds: $215K
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
0% more funds holding
Funds holding: 66 → 66 (0)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.46M |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$6.39M |
| 3 |
AC
Armistice Capital
New York
|
+$4.41M |
| 4 |
Millennium Management
New York
|
+$3.35M |
| 5 |
TLCM
Tiger Legatus Capital Management
New York
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$9.85M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$2.25M |
| 3 |
Renaissance Technologies
New York
|
-$1.46M |
| 4 |
DM
Deerfield Management
New York
|
-$1.44M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.14M |
NVLN Hedge Fund Activity: Q1 2017 in Review
66 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q1 2017, worth a combined $146M — up 33% from $110M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NVLN positions and 10 closed out — a net gain of 1 holder — while 17 added to existing stakes and 19 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $7.46M. The largest seller was Scopia Capital Management, exiting entirely with an estimated $9.85M sold.
- 66 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $146M of Novelion Therapeutics Inc. Common Shares stock for Q1 2017, up 33% quarter-over-quarter.
- 11 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q1 2017 and 10 closed out, a net change of +1 holder.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q1 2017 was Opaleye Management, an estimated $7.46M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q1 2017 was Scopia Capital Management, an estimated $9.85M sold.
Based on aggregated 13F filings for Q1 2017.